Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus

Acta Neurologica Scandinavica

Volumn 129, Issue 5, 2014, Pages 294-299

  Kellinghaus, C ^a   Berning, S ^a   Stogbauer F ^a  

^a Andreas Bannowsky Ltd   (Germany)

Author keywords

Comparison; Effect; Refractory status epilepticus; Retrospective; Tolerability

Indexed keywords

BENZODIAZEPINE; ETIRACETAM; HARKOSERIDE; PHENYTOIN; ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; PIRACETAM;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL ARTICLE; COMMUNITY HOSPITAL; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPILEPTIC STATE; FEMALE; GERMANY; HUMAN; HYPOTENSION; MALE; PATIENT IDENTIFICATION; RETROSPECTIVE STUDY; TACHYCARDIA; THROMBOCYTOPENIA; ADOLESCENT; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RETREATMENT; STATUS EPILEPTICUS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ACETAMIDES; ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PIRACETAM; RETREATMENT; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897958788     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12174     Document Type: Article

References (23)

1. Alldredge BK, Gelb AM, Isaacs SM et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001;345:631-637.
2. Silbergleit R, Durkalski V, Lowenstein D et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012;366:591-600.
3. Treiman DM, Meyers PD, Walton NY et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-798.
4. Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd GD. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures. Epilepsia 2013;54:58-65.
5. Trinka E, Höfler J, Tilz C, Kellinghaus C. Comment: lacosamide for the treatment of refractory status epilepticus. Ann Pharmacother 2012;46:765-766.
6. Höfler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013;54:393-404.
7. Kellinghaus C, Stögbauer F. Treatment of status epilepticus in a large community hospital. Epilepsy Behav 2012;23:235-240.
8. Kellinghaus C, Berning S, Immisch I et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011;123:137-141.
9. Ashton CH. Benzodiazepines - How they work and how to withdraw (The Ashton manual), 2011; http://www.benzo.org.uk/manual/ (accessed 20 April 2011).
10. Sostmann HJ, Sostmann H, Crevoisier C, Bircher J. Dose equivalence of midazolam and triazolam. A psychometric study based on flicker sensitivity, reaction time and digit symbol substitution test. Eur J Clin Pharmacol 1989;36:181-187.
11. Trinka E. What is the relative value of the standard anticonvulsants: phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam? Epilepsia 2009;50(Suppl 12):40-43.
12. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005;62:1698-1702.
13. Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res 2012;98:232-237.
14. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia 2010;51:251-256.
15. Swisher CB, Doreswamy M, Gingrich KJ, Vredenburgh JJ, Kolls BJ. Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. Neurocrit Care 2012;16:109-113.
16. Koubeissi MZ, Mayor CL, Estephan B, Rashid S, Azar NJ. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol Scand 2011;123:142-146.
17. Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ III. The use of lacosamide in refractory status epilepticus. Neurocrit Care 2011;14:348-353.
18. Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 2011;52:e148-e152.
19. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA 1983;249:762-765.
20. Detoledo JC, Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf 2000;22:459-466.
21. Binder L, Trujillo J, Parker D, Cuetter A. Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters. Am J Emerg Med 1996;14:398-401.
22. Appleton RE, Gill A. Adverse events associated with intravenous phenytoin in children: a prospective study. Seizure 2003;12:369-372.
23. Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav 2011;20:725-727.